These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38605496)

  • 1. New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series.
    Schneider M; Kramer J; Banks A; Moses H
    Mult Scler; 2024 Sep; 30(10):1379-1382. PubMed ID: 38605496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate.
    Dempsey JP; Wu L; Balshi A; Jun C; Baber U; Sloane JA
    Mult Scler Relat Disord; 2024 Sep; 89():105737. PubMed ID: 39029343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use.
    Paik J
    CNS Drugs; 2021 Jun; 35(6):691-700. PubMed ID: 34057708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
    Caldito NG; O'Leary S; Stuve O
    Mult Scler; 2021 Jul; 27(8):1306-1308. PubMed ID: 33620273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
    Lehmann-Horn K; Penkert H; Grein P; Leppmeier U; Teuber-Hanselmann S; Hemmer B; Berthele A
    Neurology; 2016 Jul; 87(4):440-1. PubMed ID: 27343070
    [No Abstract]   [Full Text] [Related]  

  • 7. Dimethyl fumarate associated lymphopenia in clinical practice.
    Longbrake EE; Cross AH
    Mult Scler; 2015 May; 21(6):796-7. PubMed ID: 25432948
    [No Abstract]   [Full Text] [Related]  

  • 8. Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis.
    Borrelli S; Mathias A; Goff GL; Pasquier RD; Théaudin M; Pot C
    Mult Scler Relat Disord; 2022 Jul; 63():103887. PubMed ID: 35636269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
    Wray S; Then Bergh F; Wundes A; Arnold DL; Drulovic J; Jasinska E; Bowen JD; Negroski D; Naismith RT; Hunter SF; Gudesblatt M; Chen H; Lyons J; Shankar SL; Kapadia S; Mendoza JP; Singer BA
    Adv Ther; 2022 Apr; 39(4):1810-1831. PubMed ID: 35211872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
    Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
    CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diroximel fumarate in the treatment of multiple sclerosis.
    Jonasson E; Sejbaek T
    Neurodegener Dis Manag; 2020 Oct; 10(5):267-276. PubMed ID: 32686599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis.
    Boullosa-Lale S; González-Freire L; Martínez-Martínez L; Crespo-Diz C
    Farm Hosp; 2020 Dec; 45(2):73-76. PubMed ID: 33709887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis.
    Andreozzi V; Capuano R; Scannapieco S; Barra F; d'Arco B; Giordano C; Caterino M; De Marca U; Di Filippo F; Di Gregorio M; Barone P
    Neurol Sci; 2024 Jun; 45(6):2807-2810. PubMed ID: 38150132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Naismith RT; Wolinsky JS; Wundes A; LaGanke C; Arnold DL; Obradovic D; Freedman MS; Gudesblatt M; Ziemssen T; Kandinov B; Bidollari I; Lopez-Bresnahan M; Nangia N; Rezendes D; Yang L; Chen H; Liu S; Hanna J; Miller C; Leigh-Pemberton R
    Mult Scler; 2020 Nov; 26(13):1729-1739. PubMed ID: 31680631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    Morales FS; Koralnik IJ; Gautam S; Samaan S; Sloane JA
    J Neurol; 2020 Jan; 267(1):125-131. PubMed ID: 31583427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.
    Baeva ME; Metz LM; Greenfield J; Camara-Lemarroy CR
    Mult Scler Relat Disord; 2023 Jun; 74():104699. PubMed ID: 37031552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
    Lucchini M; Prosperini L; Buscarinu MC; Centonze D; Conte A; Cortese A; Elia G; Fantozzi R; Ferraro E; Gasperini C; Ianniello A; Landi D; Marfia GA; Nociti V; Pozzilli C; Salvetti M; Tortorella C; Mirabella M
    J Neurol; 2021 Jun; 268(6):2238-2245. PubMed ID: 33496861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.
    Kowalec K; Kingwell E; Carruthers R; Marrie RA; Bernatsky S; Traboulsee A; Ross CJD; Carleton B; Tremlett H
    BMJ Open; 2017 Jun; 7(5):e016276. PubMed ID: 28576902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient.
    Perini P; Rinaldi F; Puthenparampil M; Marcon M; Perini F; Gallo P
    Mult Scler Relat Disord; 2018 Nov; 26():68-70. PubMed ID: 30227312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse dermatophytosis occurring on dimethyl fumarate therapy.
    Greenstein JI
    Mult Scler; 2018 Jun; 24(7):999-1001. PubMed ID: 29649923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.